MEDIFAST (MED)
(Delayed Data from NYSE)
$18.68 USD
-0.31 (-1.63%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $18.69 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Price, Consensus and EPS Surprise
MED 18.68 -0.31(-1.63%)
Will MED be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MED
Medifast Trades Near 52-Week Low: Buy, Hold or Sell MED Stock?
Medifast (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?
MED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medifast's (MED) Strategies Aid Amid Evolving Market Demands
Medifast (MED) Tumbles 25% in 3 Months: Should You Buy Now?
Medifast (MED) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
Other News for MED
Warning: MED is at high risk of performing badly
Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Medifast Business Continues To Shrink, Stock Still Risky
Analysts Offer Insights on Consumer Cyclical Companies: Penn National Gaming (PENN), Lincoln Edu (LINC) and Medifast (MED)
D.A. Davidson Sticks to Their Sell Rating for Medifast (MED)